Credit score: Anna Tarazevich from Pexels
Scripps Analysis in La Jolla announce a brand new medical trial that may assess the effectiveness of utilizing medicine permitted for diabetes therapy and weight reduction to deal with lengthy COVID-19, the debilitating power situation identified in an estimated 20 million People and about 400 million individuals worldwide.
Developed to assist individuals with sort 2 diabetes management their blood sugar ranges, these GLP-1 drugs have generated billions of {dollars} in income for his or her skill to sluggish the tempo of digestion and cut back urge for food, serving to hundreds of thousands worldwide drop some weight.
However, as all the time occurs with huge pharma blockbusters, the analysis neighborhood is busy exploring different attainable functions for this class of compounds, with medical trials underway or forming in heart problems, power kidney illness and obstructive sleep apnea.
And rising proof of its anti-inflammation properties, notes Scripps computational biologist and research co-principal investigator Julia Vogel, has pushed rising curiosity in utilizing GLP-1 medicine to deal with not less than a few of lengthy COVID’s myriad signs, which vary from mind fog and issue respiratory to fatigue and joint ache.
The trial, which seeks to enroll 1,000 lengthy COVID sufferers nationwide, will discover how self-administration of tirzepatide, Eli Lilly’s GLP-1 agonist marketed as Mounjaro for diabetes therapy and Zepbound for weight reduction, impacts signs over a 12-month interval.
“GLP-1 drugs have been found to do so many different things,” Vogel mentioned. “They’ve helped with all kinds of immune conditions, in part by reducing inflammation, and we know that is an issue in long COVID.”
“We’ve heard anecdotal reports of people who literally, on their first shot, just feel like their symptoms are just clearing, like they didn’t even realize that they had so much anxiety until it was just gone,” Vogel mentioned.
Given that there’s at the moment no drug to deal with lengthy COVID regardless of greater than $1 billion in spending on analysis by the federal authorities, the likelihood that GLP-1 medicine are useful on this area is extraordinarily interesting. Nonetheless, anecdotal proof won’t ever persuade medical health insurance firms to cowl such prescriptions, nor docs to broadly write prescriptions with out proof of efficacy. These are the targets of the brand new Scripps Analysis research.
Dr. Eric Topol, the research’s co-principal investigator and a widely known Scripps vice chairman, famous that no trials to this point, and there have been only a few to date, have met the extent of rigor that can be employed for the Lengthy COVID Remedy Trial.
“There has still not been a large, randomized, placebo-controlled trial of a candidate drug,” Topol mentioned. “That is what we have started this week with tirzepatide.”
Trial protocols name for half of the 1,000 contributors to obtain a placebo, inert doses that don’t have any impact, somewhat than the lively drug, making a management group that’s important to acquiring scientifically legitimate outcomes.
Scripps Analysis, he famous, has written many papers on lengthy COVID for the reason that pandemic. A paper {that a} group of researchers revealed in January 2023 titled “Long COVID: major findings, mechanisms and recommendations” that particulars how this lingering sickness impacts many various programs of the physique has been notably effectively acquired, with practically 2 million views.
Vogel herself suffers lengthy COVID fatigue so extreme that the previous distance runner was compelled to start utilizing a wheelchair and go away San Diego, rejoining her prolonged household on the East Coast. It was seeing one in every of their very own so severely affected by the situation, Topol mentioned, that spurred a robust dedication to lengthy COVID analysis.
GLP-1 medicine, together with Ozempic and Wegovy from Novo Nordisk, are designed to be self-administered, with sufferers giving themselves photographs as soon as per week. This truth allowed the Scripps group to create a “digital” trial that mails provides to contributors somewhat than requiring them to journey to medical websites as many trials do.
Individuals, who should have medical documentation of lengthy COVID, will obtain 4 doses of tirzepatide within the mail, beginning with decrease concentrations of the lively ingredient and rising over six months to search out every participant’s “optimal dose,” Vogel mentioned.
“We ask them to report their weight and any side effects every week and then each month, before their next shipment, there’s a discussion with one of the study physicians about, ‘OK, are you still having any side effects?'” Vogel mentioned. “In the event that they’re nonetheless having any negative effects, (the dose) doesn’t go up.
“If they’re feeling better and they’re interested in going up, then they can, or they can just choose to stay where they are.”
Individuals should repeatedly file their fatigue stage utilizing a particular smartphone utility in order that researchers can perceive how the drug impacts this key measurement.
“We’re also going to be sending everyone a wearable (electronic monitor) so they will have this passive monitoring of their daily step count, their heart rate, heart rate variability, sleep, etc.,” Vogel mentioned.
Fifty contributors can be requested to go one step additional, utilizing a particular gadget that may gather blood samples from the higher arm with the press of a button. These collections will permit deeper evaluation of biomarkers and different elements that may be correlated with self-reported fatigue assessments and wearable knowledge to offer a fuller image of the organic results of the drug.
Along with a protracted COVID prognosis, contributors should be not less than 18 years of age with web entry, a “fatigue severity scale score” of not less than 36 and be prepared to observe research protocols. Pregnant ladies are excluded due to the unknown potential dangers of the drug to unborn infants.
These already taking tirzepatide, or another GLP-1 drug, are additionally excluded, in line with protocols posted on clinicaltrials.gov, as are these with sure medical situations or medical histories that researchers have decided may confound outcomes. Individuals should additionally not be within the “underweight” class with a physique mass index lower than 18.5.
As co-principal investigator, Vogel can be barred from taking part.
Is that this bittersweet, given all that she has been by since she first began experiencing life-altering signs?
“Even if the drug does not decrease the symptom burden as we hope, we will learn a lot about its effects on people with Long COVID, and if it does help, I’ll be beyond thrilled.”
2025 The San Diego Union-Tribune. Distributed by Tribune Content material Company, LLC.
Quotation:
Can a weight reduction and diabetes drug deal with lengthy COVID? (2025, November 2)
retrieved 2 November 2025
from https://medicalxpress.com/information/2025-10-weight-loss-diabetes-drug-covid.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
